OptiMARK® is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide (gadoversetamide), for use as a paramagnetic MRI contrast agent. OptiMARK® (gadoversetamide injection) is to be administered by intravenous injection. OptiMARK® is indicated for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

(OMP) Various mixtures of gastrointestinal diamagnetic contrast agents for use as negative oral contrast agents to darken the bowel.

Short name: P760, chemical compound: tetraazacyclododecanetetraacetic acid (DOTA), central moity: Gd
P760 (Guerbet SA) is a low-diffusion gadolinium complex with a macrocyclic core based on a tetraazacyclododecanetetraacetic acid (DOTA) structure, which is substituted with bulky hydrophilic groups. The relaxivity of P760 at 0.47 T is very high compared to Gd-DOTA.

Short name: PION, generic name: Polycrystalline iron oxide nanoparticles, central moiety: Fe2+/Fe3+, relaxivity: T2*enhanced, r2//r1=4.4, r2//r1=7
A substance under development (preclin.) as an RES-directed MRI contrast agent (larger particles = DDM 128, PION-ASF) for MR lymphography and the detection of liver lesions.

Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.